All News
Filter News
Found 118 articles
-
Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
7/8/2021
Cyclerion Therapeutics, Inc. and Beacon Biosignals announced an extended and expanded strategic partnership between the two companies.
-
Cyclerion Therapeutics Announces $18 Million Private PlacementProceeds to fund ongoing clinical development of CY6463 and advancement of next generation CY3018 program
6/4/2021
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced a direct private sale of approximately $18 million of Cyclerion shares of common stock to EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners, LP, Invus, Peter Hecht, Ph.D., Lincoln Park Capital Fund, LLC and Polaris Partners.
-
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
6/4/2021
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that it has entered into an exclusive, global license agreement with Akebia Therapeutics, Inc., a leading biopharmaceutical company focused on kidney disease, for the development and commercialization of praliciguat, an oral sGC stimulator.
-
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
5/27/2021
Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator Oral, once-daily CY6463 is being developed for neurological diseases associated with cognitive impairment
-
Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference - May 25, 2021
5/25/2021
Cyclerion Therapeutics, Inc. announced that Company management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET.
-
Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
4/27/2021
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, hosted a webinar today to provide clinical updates for its first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator CY6463 in Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS)
-
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of DirectorsSenior CNS expert and biotech business leader to inform strategy and future clinical development
4/26/2021
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced the appointment of Errol De Souza, Ph.D., to its board of directors.
-
Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
4/21/2021
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Cheryl Gault, Chief Operating Officer will present a corporate overview at B. Riley’s Neuroscience Investor Conference on Thursday, April 29, 2021 at 1:00 p.m. ET.
-
Cyclerion Therapeutics to Host Pipeline Update Webinar
4/20/2021
Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase 1b clinical trial in CIAS
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
AavantiBio Appoints Dr. Christopher Wright as Chief Medical Officer
3/30/2021
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Christopher Wright, M.D., Ph.D., as Chief Medical Officer.
-
TransMedics Appoints Stephanie Lovell to Board of Directors
3/24/2021
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Stephanie Lovell to its Board of Directors and as a member of the Nominating and Corporate Governance Committee, effective March 22, 2021.
-
Cyclerion Therapeutics Announces Departure of Chief Medical Officer
3/18/2021
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Christopher Wright, M.D., Ph.D., Chief Medical Officer, has resigned his position with the company. He will provide Cyclerion with transitional support until March 26, 2021 and will join the Company’s Clinical Advisory Board.
-
Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
2/25/2021
Novel mechanism of CY6463 demonstrated desired blood brain barrier penetration, target engagement, favorable safety and tolerability profile as well as evidence in multiple independent biomarkers associated with cognitive impairment, including neuroinflammatory biomarkers; MELAS Phase 2a study underway with top-line data anticipated in mid-2021; Phase 2a study Alzheimer’s disease with vascular pathology expected to initiate in mid-2021;
-
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance
2/17/2021
Iron Pharmaceuticals to report 2020 results – LINZESS ® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% –
-
Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
1/25/2021
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of clinical and scientific advisory boards comprised of academic leaders with expertise in CNS diseases
-
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
1/4/2021
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system (CNS), today announced that it will present a corporate overview at upcoming investor conferences:
-
Cyclerion Announces Leadership Transitions
12/21/2020
Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor Cheryl Gault promoted to Chief Operating Officer Amy Schulman stepping down from Board of Directors
-
Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
11/5/2020
Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant i mprovements in multiple measures associated with age-related cognitive decline and neurodegenerative diseases Company revamping its organization to focus on critical IW-6463 CNS program priorities; expects 2021 average cash use reduction of approximately 50% from Q3 2020 levels
-
Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance
11/5/2020
U.S. LINZESS® (linaclotide) net sales increased 10% year-over-year to $241 million, as reported by AbbVie Inc. (AbbVie)